• Home
  • Authors
  • Write for us
  • Advertise
  • Contact
  • Privacy Policy
  • Terms and Conditions
Sunday, April 11, 2021
No Result
View All Result
ABC Money
PR Fire Press Release Distribution
  • News
  • Business
  • Economics
  • Finance
    • Investment
    • Tax
    • Mortgage
  • Property
    • Utilities
  • World
  • Technology
  • Fashion
  • Health
  • Holidays
  • News
  • Business
  • Economics
  • Finance
    • Investment
    • Tax
    • Mortgage
  • Property
    • Utilities
  • World
  • Technology
  • Fashion
  • Health
  • Holidays
ABC Money
No Result
View All Result
Home Business

U.S. FDA restricts use of Glaxo’s Advair

by Joseph Beale
14/12/2017

LONDON: The U.S. Food and Drug Administration had directed that drugmaker GlaxoSmithKline’s biggest selling asthmatic drug Advair should be made available to asthmatics only as a last resort. The ruling is likely to hit the drug major really hard as Advair is its single most important drug.

The drug, which had recorded a worldwide sale of 3.43 billion pounds last year, is predicted to become a 5-billion-pound-a-year earner for the company by 2010. In the U.S., almost a quarter of the drug’s sales come from prescriptions as a first line of treatment.

Experts feel that while FDA rulings carry extreme importance and are likely to be followed, U.S. doctors would continue to prescribe the drug and patients, who are used to the benefits of the dual-action inhaler, may not leave it.

In Europe, where regulators are stricter, Advair sales are currently 15 per cent ahead of last year.

The ruling naturally brought the company’s shares down by almost 4 per cent yesterday.

The FDA has acted in the wake of recent clinical trials, which showed Advair and similar drugs had occasionally triggered sudden asthma attacks in its patients, some of which were fatal. It proposed a more restrictive labelling system for the drug.

Glaxo has criticised the ruling, saying the drug has been a boon to millions of patients worldwide and the recommendation that it can be used as a second line of treatment could lead to deaths of those who are best suited to receive it immediately.

The company’s vice president for clinical development and medical affairs, Dr Kathy Rickard, said FDA’s proposed labelling changes would reserve the most effective asthma treatment until after a patient has failed on other treatment options and therefore may be at risk for severe outcomes, such as exacerbations and potentially death.

RelatedPosts

About Evangelos Marinakis

XNSPY Review: The Best Spy App for Both Android- and iOS-based devices [TESTED]

A Step by Step Guide to Making Money with Social network

A Step By Step Guide To Create SEO Friendly Article

Load More

A company spokesperson said the existing U.S. label for the drug contains a strong enough caveat in the form of a “black box” warning, introduced in 2003.

The company has a month to respond to the FDA ruling before the final text for the product’s labels are agreed. Glaxo has confirmed it intends to appeal.

Previous Post

RCN warns of severe shortage of nurses

Next Post

Daniel Radcliffe richest UK teen, £23 million in the bank, more to come

Related Posts

About Evangelos Marinakis
Business

About Evangelos Marinakis

09/04/2021
XNSPY Review: The Best Spy App for Both Android- and iOS-based devices [TESTED]
Business

XNSPY Review: The Best Spy App for Both Android- and iOS-based devices [TESTED]

08/04/2021
A Step by Step Guide to Making Money with Social network
Business

A Step by Step Guide to Making Money with Social network

08/04/2021
Next Post
Daniel Radcliffe richest UK teen, £23 million in the bank, more to come

Daniel Radcliffe richest UK teen, £23 million in the bank, more to come

Blair, government under attack for flu vaccine bungling

MoD burdened with £2.7 billion overspend bill

Latest News

WHY IS MARC RANDAZZA STILL AN ATTORNEY - DISBAR ATTORNEY RANDAZZA

WHY STATE BAR OF NEVADA ALLOWS CORRUPT MARC RANDAZZA TO PRACTICE LAW?

10/04/2021
Things Cryptopunks Nfts And The Mona Lisa Have In Common

Things Cryptopunks Nfts And The Mona Lisa Have In Common

10/04/2021
Exodus Allows You To Acquire Your Shares From Your Own Bitcoin Wallet

Exodus Allows You To Acquire Your Shares From Your Own Bitcoin Wallet

10/04/2021
Copy trading

Copy trading

09/04/2021
Trading on the China A50

Money Back Review – Get Your Money Back From Investment and Trading Scams

09/04/2021
Bitcoin: High risk at what reward?

Key to success in Bitcoins

09/04/2021

Social

Contact

For editorial enquiries:

editorials@abcmoney.co.uk

For advertising enquiries:

advertise@abcmoney.co.uk

Top Topics

  • News
  • Business
  • Finance
  • Property
  • Technology
  • Investment

Guides

  • Best UK Bridging Loans
  • Best UK Secured Loans
  • Best UK Commercial Mortgages
  • Best UK Business Loans
  • Best UK Payday Loans
  • Best Sites for International Money Transfers
  • Best Press Release Distribution Service

Social

  • Home
  • Authors
  • Write for us
  • Advertise
  • Contact
  • Privacy Policy
  • Terms and Conditions

© 2020 ABC Money

No Result
View All Result
  • Write for us
  • Contact
  • About Us
    • Authors
  • News Desk
    • Business
    • Finance
    • Property
    • Technology
    • Investment

© 2020 ABC Money

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.